Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Laurence Gladieff1, Dominique Stoppa Lyonnet2, Alain Lortholary3

  • 1Département d'oncologie médicale, institut Claudius-Regaud, 1, avenue Irène-Joliot-Curie, IUCT-Oncopole, 31059 Toulouse, Cedex 9, France.

Bulletin Du Cancer
|June 20, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial.

Translational oncology·2026
Same author

No prognostic role for FIGO grading in mismatch repair deficient endometrial carcinoma.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.

NPJ precision oncology·2026
Same author

Highlights from the 27th European Congress on Gynecological Oncology in Copenhagen: interview compilation of the ENYGO-IJGC editorial fellows.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Follow-up, cancer risk and mortality in Peutz-Jeghers syndrome: Data from the PRED-IdF network.

European journal of human genetics : EJHG·2026
Same author

Ovarian central nervous system-type tumors: integrated neuropathological and methylation-based classification reveals site-related features.

Acta neuropathologica communications·2026
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
See all related articles
This summary is machine-generated.

Genetic counseling is now essential for women diagnosed with ovarian cancer, guiding BRCA gene testing and PARP inhibitor prescriptions like olaparib. This ensures personalized treatment for BRCA-mutated ovarian carcinomas.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • PARP inhibitors have altered treatment paradigms for relapsed ovarian carcinoma.
  • Oncogenetic counseling is now integral to managing BRCA gene mutations.

Purpose of the Study:

  • To outline the modified pathways for oncogenetic counseling following the introduction of PARP inhibitors.
  • To detail the recommendations for BRCA testing and its integration with counseling in ovarian cancer management.

Main Methods:

  • Review of current clinical guidelines and treatment protocols for ovarian cancer.
  • Description of the process for oncogenetic counseling, including fast-track pathways for somatic analysis.
  • Analysis of olaparib's current indications and prescription criteria.
Keywords:
BRCA mutationCancer de l’ovaire de haut gradeConsultation d’oncogénétiqueHigh grade ovarian carcinomaMutation BRCAOlaparibOncogenetic counselingRechuteRecurrent diseaseTraitementTreatment

Related Experiment Videos

Main Results:

  • BRCA testing is recommended for all high-grade serous ovarian, fallopian tube, or peritoneal adenocarcinoma diagnoses, irrespective of age or family history.
  • Oncogenetic counseling must accompany all constitutional BRCA1/BRCA2 mutation investigations.
  • Olaparib is indicated for BRCA-mutated ovarian cancers in sensitive platinum relapse, requiring close monitoring for toxicities.

Conclusions:

  • The integration of genetic counseling and BRCA testing is crucial for optimizing PARP inhibitor therapy in ovarian cancer.
  • Treatment decisions, including olaparib prescription, should be made within a multidisciplinary team, especially for non-serous carcinomas.